Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
Summary
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes,...
Description
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes,...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source